News
5 December 2022
BioXmark® demonstrates strong performance to enable radiotherapy boosting in rectal cancer patients
Read more15 June 2022
BioXmark® enables smaller PTV margins and may allow a significantly increased radiation dose escalation to rectal cancers
Read more13 June 2022
BioXmark®, the liquid fiducial marker can be successfully implanted in stomach cancer patients for IGRT target identification
Read more1 April 2022
BioXmark® is made available for all participants in the PROTECT esophagus cancer trial
Read more17 December 2021
BioXmark® shows promising clinical results for intraoperative marking of tumor resection surface to guide postoperative radiotherapy of oral cancer
Read more26 August 2021
European patent approval completes strong worldwide IP protection of BioXmark® as a unique liquid fiducial marker
Read more22 June 2021
Use of BioXmark® to refine preclinical image-guided radiotherapy presented by Dr. Butterworth in an Xstrahl webinar
Read more4 May 2021
BioXmark® can provide a fast and reliable option for intraoperative marking of tumor resection surface in oral cancer patients
Read more16 September 2020
Publication of the technology behind Nanovi’s liquid fiducial markers reveals broad application potential in radiation therapy and surgery
Read more15 September 2020
BioXmark® improves target delineation and is suitable for Small Animal Image-Guided Radiation Therapy (SAIGRT)
Read more12 August 2020
BioXmark® demonstrates good performance and safety for IGRT in bladder cancer
Read more8 June 2020
BioXmark® shows good feasibility and clinical performance in esophageal cancer IGRT study
Read more3 March 2020
Nanovi earns CE mark approval for BioXmark®, its novel liquid fiducial marker
Read more25 November 2019
Global radiation therapy market specialist joins Nanovi’s board of directors
Read more12 June 2018
Nanovi secures DKK 15 million in funding from new and existing life science investors
Read more11 December 2017